Millendo Therapeutics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.24 million shs
Average Volume2.21 million shs
Market Capitalization$26.08 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for Millendo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Millendo Therapeutics logo

About Millendo Therapeutics

Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.40 out of 5 stars

Medical Sector

732nd out of 2,099 stocks

Pharmaceutical Preparations Industry

362nd out of 831 stocks

Analyst Opinion: 3.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

Is Millendo Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Millendo Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLND, but not buy additional shares or sell existing shares.
View analyst ratings for Millendo Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Millendo Therapeutics?

Wall Street analysts have given Millendo Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Millendo Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest in May. As of May 28th, there was short interest totaling 1,980,000 shares, an increase of 28.6% from the May 13th total of 1,540,000 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is currently 1.2 days. Approximately 12.3% of the company's stock are short sold.
View Millendo Therapeutics' Short Interest

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, June 18th 2021.
View our earnings forecast for Millendo Therapeutics

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics, Inc. (NASDAQ:MLND) announced its quarterly earnings results on Sunday, March, 28th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.05.
View Millendo Therapeutics' earnings history

How has Millendo Therapeutics' stock price been impacted by Coronavirus?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MLND shares have decreased by 79.2% and is now trading at $1.37.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MLND?

4 brokers have issued 12 month target prices for Millendo Therapeutics' shares. Their forecasts range from $2.00 to $6.00. On average, they expect Millendo Therapeutics' stock price to reach $3.67 in the next year. This suggests a possible upside of 167.6% from the stock's current price.
View analysts' price targets for Millendo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:
  • Dr. Julia C. Owens Ph.D., Exec. Chair of Board (Age 47, Pay $798k)
  • Mr. Louis J. Arcudi III, M.B.A., MBA, CEO, Pres & Director (Age 60, Pay $538.31k)
  • Ms. Jennifer Lynn Minai-Azary, CFO & Principal Accounting Officer
  • Mr. Jeffery M. Brinza J.D., Interim Gen. Counsel (Age 59)
  • Ms. Denise Dorigo Jones, VP of HR
  • Mr. Thomas Hoover, Chief Bus. Officer

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bionano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX).

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

Who are Millendo Therapeutics' major shareholders?

Millendo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (7.08%), Renaissance Technologies LLC (4.86%), Monashee Investment Management LLC (2.63%), Acadian Asset Management LLC (1.53%), BlackRock Inc. (0.73%) and Knott David M (0.72%).

Which major investors are selling Millendo Therapeutics stock?

MLND stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, and Goldman Sachs Group Inc..

Which major investors are buying Millendo Therapeutics stock?

MLND stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Monashee Investment Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Knott David M, Squarepoint Ops LLC, Dimensional Fund Advisors LP, and BlackRock Inc..

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $1.37.

How much money does Millendo Therapeutics make?

Millendo Therapeutics has a market capitalization of $26.08 million.

How many employees does Millendo Therapeutics have?

Millendo Therapeutics employs 12 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is

Where are Millendo Therapeutics' headquarters?

Millendo Therapeutics is headquartered at 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.